Developmental programming: Insulin sensitizer treatment improves reproductive function in prenatal testosterone-treated female sheep

Endocrinology

Volumn 151, Issue 8, 2010, Pages 4007-4017

  Veiga Lopez, Almudena ^a   Lee, James S ^a   Padmanabhan, Vasantha ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; ROSIGLITAZONE; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREEDING; CHEMICAL ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENITAL SYSTEM DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER FUNCTION; NONHUMAN; OVARY CYCLE; PRIORITY JOURNAL; REPRODUCTION; SHEEP;

ANIMALS; DRUG EVALUATION, PRECLINICAL; ESTROUS CYCLE; FEMALE; FETAL DEVELOPMENT; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIVER; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; REPRODUCTION; SHEEP; TESTOSTERONE; THIAZOLIDINEDIONES;

EID: 77954928402     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0124     Document Type: Article

References (72)

1. Homburg R, Giudice LC, Chang RJ 1996 Polycystic ovary syndrome. Hum Reprod 11:465-466
2. Rosenfield RL 1997 Current concepts of polycystic ovary syndrome. Baillieres Clin Obstet Gynaecol 11:307-333
3. Ehrmann DA 2000 Glucose intolerance in the polycystic ovary syndrome: role of the pancreatic β-cell. J Pediatr Endocrinol Metab 13(Suppl 5):1299-1301
4. Ben-Haroush A, Yogev Y, Fisch B 2004 Insulin resistance and metformin in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 115:125-133
5. Diamanti-Kandarakis E, Xyrafis X, Boutzios G, Christakou C 2008 Pancreatic β-cells dysfunction in polycystic ovary syndrome. Panminerva Med 50:315-325
6. Dunaif A 1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774-800
7. Goverde AJ, van Koert AJ, Eijkemans MJ, Knauff EA, Westerveld HE, Fauser BC, Broekmans FJ 2009 Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod 24:710-717
8. Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I, Spinas GA, Carmina E 2009 Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. Int J Clin Pract 63:56-62
9. Bethea SW, Nestler JE 2008 Comorbidities in polycystic ovary syndrome: their relationship to insulin resistance. Panminerva Med 50:295-304
10. Hoffman LK, Ehrmann DA 2008 Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 4:215-222 (Pubitemid 351430905)
11. Benson S, Arck PC, Tan S, Hahn S, Mann K, Rifaie N, Janssen OE, Schedlowski M, Elsenbruch S 2009 Disturbed stress responses in women with polycystic ovary syndrome. Psychoneuroendocrinology 34:727-735
12. Moran LJ, Brinkworth GD, Norman RJ 2008 Dietary therapy in polycystic ovary syndrome. Semin Reprod Med 26:85-92
13. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH 2010 Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiroinositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev CD003053
14. Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, Dodson WC 2007 The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 196:402.e1-402.e10; discussion 402.e10-402.e11
15. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE 2004 Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 82:893-902 (Pubitemid 39346435)
16. Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, Lanzone A 2003 Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 18:1210-1218 (Pubitemid 36740566)
17. Mitwally MF, Kuscu NK, Yalcinkaya TM 1999 High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod 14:2700-2703 (Pubitemid 29520675)
18. Brettenthaler N, De Geyter C, Huber PR, Keller U 2004 Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:3835-3840 (Pubitemid 39071481)
19. Zhou R, Bruns CM, Bird IM, Kemnitz JW, Goodfriend TL, Dumesic DA, Abbott DH 2007 Pioglitazone improves insulin action and normalizes menstrual cycles in a majority of prenatally androgenized female rhesus monkeys. Reprod Toxicol 23:438-448 (Pubitemid 46602932)
20. Ibáñez L, de Zegher F, Potau N 1998 Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. J Endocrinol Invest 21:558-566 (Pubitemid 28532463)
21. Apter D 1998 Endocrine and metabolic abnormalities in adolescents with a PCOS-like condition: consequences for adult reproduction. Trends Endocrinol Metab 9:58-61 (Pubitemid 28207614)
22. Blank SK, McCartney CR, Helm KD, Marshall JC 2007 Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty. Semin Reprod Med 25:352-359
23. Rosenfield RL 2007 Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 92:787-796
24. Kent SC, Gnatuk CL, Kunselman AR, Demers LM, Lee PA, Legro RS 2008 Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 93:1662-1669 (Pubitemid 351656502)
25. Franks S 2008 Polycystic ovary syndrome in adolescents. Int J Obes (Lond) 32:1035-1041
26. Dumesic DA, Abbott DH, Padmanabhan V 2007 Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord 8:127-141
27. Abbott DH, Bruns CM, Barnett DK, Tarantal AF, Hoffmann SM, Zhou R, Levine JE, Dumesic DA 2008 Fetal origins of the polycystic ovarian syndrome. In: Dunaif A, Chang RJ, Franks S, Legro RS, eds. Polycystic ovarian syndrome. 1st ed. Totowa, NJ: Humana Press; 87-106
28. Padmanabhan V, Manikkam M, Recabarren S, Foster D 2006 Prenatal testosterone excess programs reproductive and metabolic dysfunction in the female. Mol Cell Endocrinol 246:165-174 (Pubitemid 43238412)
29. Birch RA, Padmanabhan V, Foster DL, Unsworth WP, Robinson JE 2003 Prenatal programming of reproductive neuroendocrine function: fetal androgen exposure produces progressive disruption of reproductive cycles in sheep. Endocrinology 144:1426-1434 (Pubitemid 36428485)
30. Steckler T, Manikkam M, Inskeep EK, Padmanabhan V 2007 Developmental programming: follicular persistence in prenatal testosterone-treated sheep is not programmed by androgenic actions of testosterone. Endocrinology 148:3532-3540
31. Veiga-Lopez A, Ye W, Phillips DJ, Herkimer C, Knight PG, Padmanabhan V 2008 Developmental programming: deficits in reproductive hormone dynamics and ovulatory outcomes in prenatal, testosterone-treated sheep. Biol Reprod 78:636-647
32. Manikkam M, Steckler TL, Welch KB, Inskeep EK, Padmanabhan V 2006 Fetal programming: prenatal testosterone treatment leads to follicular persistence/luteal defects; partial restoration of ovarian function by cyclic progesterone treatment. Endocrinology 147:1997-2007
33. Clarke IJ, Scaramuzzi RJ, Short RV 1977 Ovulation in prenatally androgenized ewes. J Endocrinol 73:385-389
34. Unsworth WP, Taylor JA, Robinson JE 2005 Prenatal programming of reproductive neuroendocrine function: the effect of prenatal androgens on the development of estrogen positive feedback and ovarian cycles in the ewe. Biol Reprod 72:619-627
35. Sarma HN, Manikkam M, Herkimer C, Dell'Orco J, Welch KB, Foster DL, Padmanabhan V 2005 Fetal programming: excess prenatal testosterone reduces postnatal luteinizing hormone, but not follicle-stimulating hormone responsiveness, to estradiol negative feedback in the female. Endocrinology 146:4281-4291
36. Sharma TP, Herkimer C, West C, Ye W, Birch R, Robinson JE, Foster DL, Padmanabhan V 2002 Fetal programming: prenatal androgen disrupts positive feedback actions of estradiol but does not affect timing of puberty in female sheep. Biol Reprod 66:924-933
37. Veiga-Lopez A, Astapova OI, Aizenberg EF, Lee JS, Padmanabhan V 2009 Developmental programming: contribution of prenatal androgen and estrogen to estradiol feedback systems and periovulatory hormonal dynamics in sheep. Biol Reprod 80:718-725
38. Robinson JE, Forsdike RA, Taylor JA 1999 In utero exposure of female lambs to testosterone reduces the sensitivity of the gonadotropin-releasing hormone neuronal network to inhibition by progesterone. Endocrinology 140:5797-5805
39. Wood RI, Foster DL 1998 Sexual differentiation of reproductive neuroendocrine function in sheep. Rev Reprod 3:130-140
40. West C, Foster DL, Evans NP, Robinson J, Padmanabhan V 2001 Intra-follicular activin availability is altered in prenatally-androgenized lambs. Mol Cell Endocrinol 185:51-59
41. Steckler T, Wang J, Bartol FF, Roy SK, Padmanabhan V 2005 Fetal programming: prenatal testosterone treatment causes intrauterine growth retardation, reduces ovarian reserve and increases ovarian follicular recruitment. Endocrinology 146:3185-3193
42. Smith P, Steckler TL, Veiga-Lopez A, Padmanabhan V 2009 Developmental Programming: differential effects of prenatal testosterone and dihydrotestosterone on follicular recruitment, depletion of follicular reserve, and ovarian morphology in sheep. Biol Reprod 80:726-736
43. Recabarren SE, Padmanabhan V, Codner E, Lobos A, Durán C, Vidal M, Foster DL, Sir-Petermann T 2005 Postnatal developmental consequences of altered insulin sensitivity in female sheep treated prenatally with testosterone. Am J Physiol Endocrinol Metab 289:E801-E806
44. Padmanabhan V, Veiga-Lopez A, Abbott DH, Recabarren SE, Herkimer C 2010 Developmental programming: impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity index and transfer of traits to offspring of overweight females. Endocrinology 151:595-605
45. Manikkam M, Crespi EJ, Doop DD, Herkimer C, Lee JS, Yu S, Brown MB, Foster DL, Padmanabhan V 2004 Fetal programming: prenatal testosterone excess leads to fetal growth retardation and postnatal catch-up growth in sheep. Endocrinology 145:790-798
46. Yilmaz M, Biri A, Karakoç A, Törüner F, Bingöl B, Cakir N, Tiras B, Ayvaz G, Arslan M 2005 The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest 28:1003-1008 (Pubitemid 43265766)
47. Yilmaz M, Karakoç A, Törüner FB, Cakir N, Tiras B, Ayvaz G, Arslan M 2005 The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol 21:154-160 (Pubitemid 41597556)
48. Roy KK, Baruah J, Sharma A, Sharma JB, Kumar S, Kachava G, Karmakar D 2010 A prospective randomized trial comparing the clinical and endocrinological outcome with rosiglitazone versus laparoscopic ovarian drilling in patients with polycystic ovarian disease resistant to ovulation induction with clomiphene citrate. Arch Gynecol Obstet 281:939-944
49. Shokeir T, El-Kannishy G 2008 Rosiglitazone as treatment for clomiphene citrate-resistant polycystic ovary syndrome: factors associated with clinical response. J Womens Health (Larchmt) 17:1445-1452
50. Marcy TR, Britton ML, Blevins SM 2004 Second-generation thiazolidinediones and hepatotoxicity. Ann Pharmacother 38:1419-1423
51. Floyd JS, Barbehenn E, Lurie P, Wolfe SM 2009 Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf 18:1238-1243
52. McMorran M, Vu D 2001 Rosiglitazone (Avandia): hepatic, cardiac and hematological reactions. CMAJ 165:82-83, 86-87
53. Smith BP 2002 Large animal internal medicine. 3rd ed. Philadelphia: Mosby
54. Aitken ID 2007 Diseases of sheep. 4th ed. Malden, MA: Blackwell Science
55. Padmanabhan V, Evans NP, Dahl GE, McFadden KL, Mauger DT, Karsch FJ 1995 Evidence for short or ultrashort loop negative feedback of gonadotropin- releasing hormone secretion. Neuroendocrinology 62:248-258
56. Matsuda M, DeFronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470
57. Foster DL, Jackson LM, Padmanabhan V 2006 Programming of GnRH feedback controls timing puberty and adult reproductive activity. Mol Cell Endocrinol 254-255:109-119
58. Phillip G 2000 Permutation tests: a practical guide to resampling methods for testing hypotheses. 2nd ed. New York: Springer
59. Kaneko JJ, Harvey JW, Bruss ML 1997 Clinical biochemistry of domestic animals. 5th ed. San Diego: Academic Series
60. Steckler TL, Herkimer C, Dumesic DA, Padmanabhan V 2009 Developmental programming: excess weight gain amplifies the effects of prenatal testosterone excess on reproductive cyclicity: implication for polycystic ovary syndrome. Endocrinology 150:1456-1465
61. Lord JM, Flight IH, Norman RJ 2003 Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev CD003053
62. De Leo V, la Marca A, Petraglia F 2003 Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24:633-667
63. Lebovitz HE, Kreider M, Freed MI 2002 Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 25:815-821
64. Wiesenberg I, Missbach M, Carlberg C 1998 The potential role of the transcription factor RZR/ROR as a mediator of nuclear melatonin signaling. Restor Neurol Neurosci 12:143-150
65. Karasek M, Winczyk K 2006 Melatonin in humans. J Physiol Pharmacol 57(Suppl 5):19-39
66. Goodman RL, Bittman EL, Foster DL, Karsch FJ 1982 Alterations in the control of luteinizing hormone pulse frequency underlie the seasonal variation in estradiol negative feedback in the ewe. Biol Reprod 27:580-589
67. Poretsky L, Kalin MF 1987 The gonadotropic function of insulin. Endocr Rev 8:132-141
68. Adashi EY, Hsueh AJ, Yen SS 1981 Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology 108:1441-1449
69. Manikkam M, Thompson RC, Herkimer C, Welch KB, Flak J, Karsch FJ, Padmanabhan V 2008 Developmental programming: impact of prenatal testosterone excess on pre- and postnatal gonadotropin regulation in sheep. Biol Reprod 78:648-660
70. Willis D, Mason H, Gilling-Smith C, Franks S 1996 Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 81:302-309
71. Chen Q, Sun X, Chen J, Cheng L, Wang J, Wang Y, Sun Z 2009 Direct rosiglitazone action on steroidogenesis and proinflammatory factor production in human granulosa-lutein cells. Reprod Biol Endocrinol 7:147
72. Sam S, Legro RS, Essah PA, Apridonidze T, Dunaif A 2006 Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci USA 103:7030-7035